



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BODIPY FL prazosin

Cat. No.:	HY-D1606
CAS No.:	175799-93-6
Molecular Formula:	C ₂₈ H ₃₂ BF ₂ N ₇ O ₃
Molecular Weight:	563.41
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BODIPY FL prazosin is a fluorescent α 1-adrenergic antagonist with K _i values of 14.5, 43.3 nM for α 1a-AR and α 1b-AR, respectively. BODIPY FL prazosin also is a fluorescent ligand with the excitation and emission wavelengths are 485 and 535 nm, respectively. BODIPY FL prazosin can be used for study the differences in the subcellular localization of α 1-adrenoceptor subtypes ^{[1][2][3]} .	
IC₅₀ & Target	α 1A-adrenergic receptor 14.5 nM (K _i)	α 1B-adrenergic receptor 43.3 nM (K _i)
In Vitro	BODIPY FL prazosin (10 nM; 30 min at room temperature in 100 μ l; COS-7 cells) shows Affinity of various α 1-AR ligands with K _i values of 14.5, 43.3 nM for α 1a-AR and α 1b-AR, respectively ^[1] . BODIPY FL prazosin (100 nM, 30 min) can be used as molecular probe for the Visualization of the non-adrenoceptor binding site of α 1-adrenergic drugs in erythroleukemia cells ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

- [1]. Sugawara T, et al. Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. *Life Sci.* 2002 Mar 22;70(18):2113-24.
- [2]. Cerveny L, et al. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. *Epilepsia.* 2006 Mar;47(3):461-8.
- [3]. Fuchs R, et al. α 1-adrenergic drugs exhibit affinity to a thapsigargin-sensitive binding site and interfere with the intracellular Ca²⁺ homeostasis in human erythroleukemia cells. *Exp Cell Res.* 2011 Dec 10;317(20):2969-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA